Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles

被引:32
作者
Berton, M [1 ]
Turelli, P
Trono, D
Stein, CA
Allémann, E
Gurny, R
机构
[1] Univ Geneva, Sch Pharm, CH-1211 Geneva, Switzerland
[2] Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland
[3] Columbia Univ Coll Phys & Surg, Dept Med & Pharmacol, New York, NY 10032 USA
关键词
phosphorothioate oligonucleoticle; nanoparticle; drug delivery; HIV-1; reverse transcription;
D O I
10.1023/A:1010962507273
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To investigate the potential use of polymeric nanoparticles for the delivery of antisense oligonucleotides in HIV-1-infected cell cultures. Methods. Phosphorothioate oligonucleotides were encapsulated into poly (D,L-lactic acid) nanoparticles. Two models of infected cells were used to test the ability of nanoparticles to deliver them. HeLa P4-2 CD4+ cells, stably transfected with the P-galactosidase reporter gone, were first used to evaluate the activity of the oligonucleotides on a single-round infection cycle. The acutely infected lymphoid CEM cells were then used to evaluate the inhibition of the viral production of HIV-1 by the oligonucleotides. Results. The addition to infected CENT cells of nanoparticles containing gag antisense oligonucleotides in the nanomolar range led to strong inhibition of the viral production in a concentration-dependent manner. Similar results were previously observed in HeLa P4-2 CD4+ cells. Nanoparticle-entrapped random-order gag oligonucleotides had similar effects on reverse transcription. However, the reverse transcriptase activity of infected cells treated with nanomolar concentrations of free antisense and random oligonucleotides was not affected. Conclusions. These results suggest that poly (D,L-lactic acid) nanoparticles may have great potential as an efficient delivery system for oligonucleotides in HIV natural target cells, i.e., lymphocytic cells.
引用
收藏
页码:1096 / 1101
页数:6
相关论文
共 30 条
[1]   Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides [J].
Agrawal, S .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :53-68
[2]   Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA [J].
Anderson, KP ;
Fox, MC ;
BrownDriver, V ;
Martin, MJ ;
Azad, RF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2004-2011
[3]   Novel mechanisms for antisense-mediated regulation of gene expression [J].
Baker, BF ;
Monia, BP .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :3-18
[4]   Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture [J].
Bennett, CF ;
Mirejovsky, D ;
Crooke, RM ;
Tsai, YJ ;
Felgner, J ;
Sridhar, CN ;
Wheeler, CJ ;
Felgner, PL .
JOURNAL OF DRUG TARGETING, 1998, 5 (03) :149-162
[5]   Uptake of oligonucleotide-loaded nanoparticles in prostatic cancer cells and their intracellular localization [J].
Berton, M ;
Benimetskaya, L ;
Allémann, E ;
Stein, CA ;
Gurny, R .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1999, 47 (02) :119-123
[6]   Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex [J].
Berton, M ;
Allémann, E ;
Stein, CA ;
Gurny, R .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 9 (02) :163-170
[7]   IMPROVED BIOLOGICAL-ACTIVITY OF ANTISENSE OLIGONUCLEOTIDES CONJUGATED TO A FUSOGENIC PEPTIDE [J].
BONGARTZ, JP ;
AUBERTIN, AM ;
MILHAUD, PG ;
LEBLEU, B .
NUCLEIC ACIDS RESEARCH, 1994, 22 (22) :4681-4688
[8]   HIV-1 REVERSE TRANSCRIPTION - A TERMINATION STEP AT THE CENTER OF THE GENOME [J].
CHARNEAU, P ;
MIRAMBEAU, G ;
ROUX, P ;
PAULOUS, S ;
BUC, H ;
CLAVEL, F .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 241 (05) :651-662
[9]   Molecular mechanisms of action of antisense drugs [J].
Crooke, ST .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1999, 1489 (01) :31-44
[10]  
Cunningham CC, 2000, CLIN CANCER RES, V6, P1626